Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values

Autor: Paschalis, Eleftherios P., Gamsjaeger, Sonja, Klaushofer, Klaus, Shane, Elizabeth, Cohen, Adi, Stepan, Jan, Pavo, Imre, Eriksen, Erik F., Taylor, Kathleen A., Dempster, David W.
Zdroj: In Bone September 2022 162
Databáze: ScienceDirect